



## Leadership Development Program Participant and Mentor/Coach Bios

### 2023-24 ASCO LDP Class



**Jesus Anampa Mesias, MD, MS** | *Montefiore Einstein Center for Cancer Care*

Dr. Jesus D. Anampa is an Associate Professor of Medicine at Albert Einstein College of Medicine in the division of Medical Oncology. Dr. Anampa earned his medical degree from Universidad Peruana Cayetano Heredia, Lima, Peru and completed hematology & Oncology fellowship at Albert Einstein College of Medicine, Bronx, NY. Dr. Anampa obtained a Master of Science degree “with distinction” in Clinical Research from Albert Einstein College of Medicine. Dr. Anampa’s clinical expertise involves treating patients with breast cancer. Dr. Anampa is a clinical trialist and translational researcher with interest in novel therapeutics, tumor microenvironment, and biomarker development. Dr. Anampa serves as the Director of Clinical and Translational breast cancer research at Montefiore Einstein Cancer Center. Dr Anampa has a special interest in racial and socioeconomic disparities in breast cancer and he participates in multiple community activities educating the Latino community about breast cancer.



**Karen Cadoo, MD** | *St. James’s Hospital*

Dr. Karen Cadoo is a Medical Oncologist and Cancer Geneticist at St. James’s Hospital (SJH) and Clinical Associate Professor, Trinity College Dublin. She co-leads the inherited cancer genetics programme at SJH and the cancer prevention pillar of the Trinity St. James’s Cancer Institute. She returned to Ireland in 2020 having spent the preceding 8 years at Memorial Sloan Kettering Cancer Center in New York where she was lead for Inherited Gynecologic Cancer Genetics. She contributes to national policy as a member of the Irish National Cancer Control Programme Hereditary Cancer Advisory Group and the National Strategy for Genetics and Genomics implementation taskforce. She runs therapeutic trials in gynecologic cancers and is a Cancer Trials Ireland representative to ENGOT. Dr. Cadoo was awarded the Irish Cancer Society Clinician Research Leadership Award 2021.



**Kristen Ciombor, MD, MS** | *Vanderbilt University*

Dr. Kristen Ciombor is an Associate Professor in the Division of Hematology/Oncology at the Vanderbilt University Medical Center in Nashville, TN. She received her medical degree from the University of Miami Miller School of Medicine in Miami, FL, where she completed both her internal medicine residency and chief residency. She then obtained her fellowship training in hematology/oncology at Vanderbilt, where she graduated with a Master of Science in Clinical Investigation as well. Dr. Ciombor specializes in the treatment of patients with gastrointestinal cancers, and her research involves the design and implementation of clinical trials for patients with GI malignancies, especially colorectal cancer. She also has a research interest in the genomics of colorectal cancer and translational medicine, and she leads multiple national investigator-initiated clinical trials in this space.



**Sepideh Gholami, MD** | *Northwell Health*

Dr. Sepideh Gholami MD, MAS is a board-certified surgeon scientist with dual fellowship training in Complex General Surgical Oncology and Hepatopancreatobiliary Surgery. Dr. Gholami serves as the Director of the Liver Multidisciplinary Clinic, Hepatic Artery Infusion Pump Program, and Translational Research in Surgical Oncology at Northwell Health. She has focused her efforts on building a multidisciplinary liver surgery program with liver-directed therapies/regional therapies, including a hepatic artery infusion pump program for patients with hepatobiliary and metastatic malignancies. Dr. Gholami's mission is to diversify and improve the research and clinical trial portfolio at Northwell Health Cancer Institute. She also has a joint appointment as an Adjunct Associate Professor at Coldspring Harbor Laboratory. Her laboratory research focuses on exploring mechanisms of immune resistance in liver metastases to develop novel immune augmenting therapies and practice-changing clinical trials to improve patient outcomes with colorectal cancer liver metastases.



**Bishal Gyawali, MD, PhD** | *Queen's University*

Bishal Gyawali, MD, PhD is a medical oncologist and an associate professor in medical oncology and public health sciences and scientist in the Division of Cancer Care and Epidemiology, in Queen's University, Kingston, Canada. His clinical expertise is across multiple adult solid tumors, with special focus on GI, GU and breast malignancies. He is in the editorial and advisory board for multiple medicine and oncology journals and has authored or co-authored more than 150 peer-reviewed articles in high-impact journals. Dr. Gyawali's areas of academic interests include cancer policy, evidence-based oncology, financial toxicities of cancer treatment, clinical trial methods, supportive care, cancer care disparities, and global oncology. He introduced the term "cancer groundshot" advocating for investments in implementation of proven interventions for global cancer control. His interviews and studies have been reported in several influential media such as CNN, NPR, Washington Post, STAT News etc. He is an expert for the WHO Drug Advisory Panel.



**Rachel Jimenez, MD** | *Massachusetts General Hospital*

Dr. Jimenez is an Associate Professor of Radiation Oncology at Harvard Medical School (HMS) and the Chair for Quality and Safety in the Department of Radiation Oncology at Massachusetts General Hospital. She holds an AB from Harvard University, an MD from HMS, and completed her residency and chief residency training in the Harvard Radiation Oncology Program. She has also completed a Fellowship in Medical Ethics at HMS. Her clinical practice focuses on the treatment of patients with breast cancer. She has special expertise in proton beam therapy and her research focuses on the reduction of late toxicity from breast radiotherapy. She is the recipient of independent grant funding from the American Society of Clinical Oncology and the Breast Cancer Research Foundation, the American Cancer Society and The Greenwall Foundation.



**Jasmine Kamboj, MD** | *Mayo Clinic*

Dr. Jasmine Kamboj is a board-certified Medical Oncologist and Hematologist at the Mayo Clinic, Rochester, Minnesota, in the Division of Community Oncology. She earned her medical degree from the Armed Forces Medical College, Pune, India. She trained in Internal Medicine at the Rosalind Franklin University of Medicine and Science, North Chicago and pursued a fellowship in Hematology and Oncology at the Baylor College of Medicine, Houston. Dr. Kamboj has served on the Health Equity and Government Relations Committees at ASCO. She has been a strong advocate at the Capitol Hill for cancer related issues, like prior authorization, that directly impact cancer care and outcomes. Dr. Kamboj has been awarded “ASCO Advocate of the year Award,” and has been honored with the highest level of Advocacy Championship, “the President’s Circle.” Dr. Kamboj currently resides in St. Paul, Minnesota, with her husband, son, and bunny.



**Catherine Lai, MD, MPH** | *University of Pennsylvania Health System*

Dr. Catherine Lai is passionate about improving clinical outcomes in acute leukemias and myeloid malignancies. Dr. Lai specializes in detection, monitoring, and treatment through clinical trial research in novel drug development and measuring physiologic age to improve early mortality and survival and minimize chemotherapy toxicity. After completing internal medicine residency at the University of Illinois Chicago, Dr. Lai completed a fellowship in hematology/oncology at the National Cancer Institute of the National Institutes of Health. Prior to joining Penn, Dr. Lai served as the Director of Leukemia at MedStar Georgetown University Hospital’s Lombardi Comprehensive Cancer Center in Washington, DC. In her current role, she is the Physician Leader of the Leukemia Clinical Research Unit. Dr. Lai received her master’s in public health in Epidemiology from George Washington University. Through her enthusiasm and leadership, Dr. Lai has partnered with the Leukemia and Lymphoma Society to establish a Philadelphia Leukemia Consortium to collaborate with local institutions.



**Roberto Leon-Ferre, MD** | *Mayo Clinic*

Dr. Leon-Ferre is an Assistant Professor of Oncology and Associate Program Director of the Advanced Breast Medical Oncology Fellowship Program at Mayo Clinic, Rochester, MN. Clinically, he is focused on breast cancer, with special focus on triple-negative breast cancer. His research seeks to understand the complex interactions between the immune system and the breast cancer tumor microenvironment, and leverage this understanding to identify predictive biomarkers and design clinical trials aimed at optimizing systemic therapy strategies. Dr. Leon-Ferre was born and raised in Ecuador, where he completed medical school. He then completed his Internal Medicine at the University of Iowa, where he served as a Chief Resident; and his Hematology and Oncology Fellowship at Mayo Clinic, where he also served as Chief fellow. At ASCO, Dr. Leon-Ferre currently serves in the ASCO Item Writing Task Force, and previously served as member and leader of the Trainee Council and Professional Development Committee.



**Samilia Obeng-Gyasi, MD, MPH** | *The Ohio State University*

Dr. Samilia Obeng-Gyasi is a breast surgical oncologist and associate professor of surgery at The Ohio State University. Her practice focuses on surgery for breast cancer and benign breast diseases. She obtained her BS in Biology (with highest distinction and departmental honors) from Indiana University-Bloomington and her MD from The University of Michigan. She completed her general surgery residency at the Cleveland Clinic and a Society of Surgical Oncology (SSO) accredited breast surgical oncology fellowship at Duke University. Due to her interest in health services research, after finishing her residency, she completed a Master's in Public Health (MPH) at the Harvard T.H. Chan School of Public Health with a focus on quantitative research methods. As a health services researcher with an emphasis on health equity, the overarching goal of her work is to understand the influence of social determinants of health on cancer initiation, progression, and mortality.



**Sandip Patel, MD** | *University of California, San Diego Moores Cancer Center*

Sandip Patel, MD is a Professor at UCSD and a Medical Oncologist focusing on early phase clinical trials of immunotherapy and thoracic oncology. He is the leader for the Experimental Therapeutics (Phase 1) Program and Deputy Director for the Center for Precision Immunotherapy at UCSD. He is co-leader of the NRG Developmental Therapeutics Committee and co-leader of the University of California Lung Cancer Consortium.



**Mohamed Salem, MD** | *Levine Cancer Institute*

Dr. Mohamed E. Salem is a distinguished gastrointestinal medical oncologist and Research Director at Atrium Health Levine Cancer Institute in Charlotte, NC, specializing in colorectal and pancreatic cancer treatment. Additionally, Dr. Salem holds the position of Associate Professor at the Wake Forest School of Medicine. Dr. Salem is internationally recognized for his expertise in gastrointestinal cancer, with a particular focus on colorectal cancer treatment, tumor molecular profiling, and precision oncology. He actively serves as a Principal Investigator in clinical trials, emphasizing gastrointestinal cancer research.

Within the American Society of Clinical Oncology, Dr. Salem holds committee roles, including the Gastrointestinal (Colorectal) Cancer Annual Meeting Education Committee and the ASCO Plenary Session Committee. He also contributes as a member of the Colon Task Force for the National Cancer Institute Gastrointestinal Steering Committee. Dr. Salem's significant contributions have garnered esteemed recognition, such as the "Molecular Cancer Research Michael B. Kastan Award for Research" in 2020.



**Ishwaria Subbiah, MS, MD | Sarah Cannon Research Institute**

Dr. Subbiah is the executive director, cancer care equity and professional wellness at Sarah Cannon Research Institute (SCRI). In this role, Dr. Subbiah will focus on reducing cancer outcomes disparities and diversifying clinical trial participation within SCRI's combined research network of over more than 1,300 physicians at over 250 locations in 24 states across the US. Dr. Subbiah will also build the organization's healthcare professional well-being program to support multidisciplinary oncology research professionals in the community.

Dr. Subbiah is a globally recognized expert in geriatric oncology, symptom management, palliative care, and healthcare professional well-being. She previously was an associate professor in the Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center. With her unique qualifications from having trained in Developmental Therapeutics, Medical Oncology, and Palliative Medicine, Dr. Subbiah has more than a decade of experience leading teams in developing and implementing organization-wide programs to improve cancer care and clinical workplace experience, including leading their integration of patient reported outcomes-based remote symptom monitoring.



**Musliu Tolani, MBBS, PG Cert PH, ChM, FWACS | Ahmadu Bello University**

Dr. Musliu Tolani works as a Senior Lecturer and Urological Surgeon at Ahmadu Bello University in Nigeria. He earned his medical degree from Ahmadu Bello University. He also holds a postgraduate certificate in Public Health and a Master of Surgery in Urology. He completed his Fellowship in Urology at the West African College of Surgeons.

Dr. Tolani's present research focuses on prostate cancer, health services, and global health. He is a recipient of numerous awards including the ASCO IDEA and LIFE awards. He leads an implementation science work on prostate cancer supported by the Prostate Cancer Foundation – Pfizer Health Equity Challenge Award.

Dr. Tolani was an ASCO Trainee and Early Career Advisory Group Liaison to the Membership Advisory Committee. He is the coordinator of the ABUTH uro-oncology multidisciplinary team and prostate cancer arm of the cancer health fund program.



**Yüksel Ürün, MD | Ankara University Faculty of Medicine**

Dr. Yüksel Ürün is a professor of medicine in the Department of Medical Oncology of Ankara University School of Medicine, Türkiye. He has been a part of Ankara University School of Medicine since 2009 and has completed his specialist training at the same institution in Turkey. Dr. Ürün also gained valuable research experience as a research fellow at the Dana Farber Cancer Institute, Harvard Medical School in Boston, USA under Prof. Toni Choueiri's mentorship. Upon returning to Turkey, Dr. Ürün established the Turkish Oncology Group Kidney Cancer Consortium (TKCC) and has led the Turkish Medical Oncology Society's genitourinary cancers guidelines group. He is an active member of various international and national oncology organizations, including the EORTC GU group, the Advanced Prostate Cancer Consensus Conference (APCCC), and serves as a faculty member in the ESMO Genitourinary Tumors, Prostate group.



**Tian Zhang, MD, MHS** | *University of Texas Southwestern Medical Center*

Dr. Zhang received her MD from the Harvard-MIT Health Sciences and Technology (HST) program and completed post-graduate training at Duke University, where she remained on faculty until 2021. She is currently Associate Professor within the Division of Hematology and Oncology and Department of Internal Medicine at University of Texas Southwestern Medical Center, Harold C. Simmons Comprehensive Cancer Center. She leads the multi-disease and precision oncology program within the cancer center and clinically specializes in genitourinary malignancies. She participates actively in the cooperative group setting and currently serves as co-chair of the NCI GU Steering Committee Renal Task Force. She is a clinical researcher focused on improving novel therapies and biomarkers for patients with renal, prostate, and urothelial cancers.

## 2023-24 ASCO LDP Mentors



**Jill Gilbert, MD, FACP, FASCO | *Vanderbilt University***

Dr. Gilbert is a Professor of Medicine and medical oncologist at Vanderbilt University who specializes in head and neck and endocrine cancers. She has extensive experience as a clinical trialist and as a medical educator, previously serving as Program Director for the hematology-oncology fellowship at Vanderbilt for over a decade. She now serves as Vice Chair of the Department of Medicine (DOM) at Vanderbilt with a focus on Faculty Development. In this role, Dr. Gilbert oversees professional development programming and faculty support for the DOM, which is comprised of a diverse group of faculty throughout the trajectory of their careers.



**Therese Mulvey, MD, FASCO | *Massachusetts General Hospital***

Therese Mulvey, MD, FASCO is the Quality, Safety and Value director for the MGH Cancer Center and the Affiliated Network Hospitals. She was previously the Director of Breast Oncology at the MGH Northshore Cancer Center, Physician in Chief for the Southcoast Cancer Center in New Bedford Massachusetts and CEO of Commonwealth Oncology, a private practice group in eastern Massachusetts.

Dr Mulvey's academic interests are in the improvement of care delivery.

Dr Mulvey graduated from Tufts University School of Medicine and trained at New England Medical Center in Internal Medicine and Medical oncology at Massachusetts General Hospital.



**Grzegorz Nowakowski, MD | *Mayo Clinic Comprehensive Cancer Center***

Grzegorz (Greg) S. Nowakowski, M.D., is a consultant and a Professor of Oncology and Medicine, Division of Hematology. He also serves as the Deputy Director of Mayo Clinic Comprehensive Cancer Center for Clinical Research and the Vice-Chair of Division of Hematology.

Dr. Nowakowski is an internationally recognized researcher and leader. His research focuses on the molecular classification and biology of lymphoproliferative disorders, new approaches to clinical trial design and novel therapies for lymphoma and hematological disorders. He is a principal investigator for multiple investigator-initiated and cooperative-group clinical trials (ECOG, Alliance) and industry-sponsored and investigator-initiated studies. He is a member of the ECOG Lymphoma Core Committee, chair of the American Society of Hematology (ASH) Clinical Trial Innovation Subcommittee, co-Chair of the ASH-FDA Regulatory Science Workshop, and chair of the American Society of Clinical Oncology (ASCO) Clinical Trial Access and Participation Taskforce.

Dr. Nowakowski has significant regulatory experience. He has served as principal investigator of regulatory studies and worked with regulatory agencies, including serving as a voting member of the Oncology Drugs Advisory Committee (ODAC) to the Food and Drug Administration (FDA). He has authored over 250 articles and numerous book chapters and mentored many faculty members in the U.S. and abroad.



**Suresh Ramalingam, MD, FACP, FASCO** | *Winship Cancer Institute of Emory University*

Board certified in medical oncology, Suresh S. Ramalingam, MD, FACP, FASCO, is nationally recognized as an investigator and a physician specializing in small and non-small cell lung cancer. Dr. Ramalingam serves as executive director of Winship Cancer Institute of Emory University and associate vice president for cancer of Woodruff Health Sciences Center. He is past-president of the Georgia Society of Oncology and a member of the board of Georgia CORE. He is a Fellow of the American Society of Clinical Oncology and a Georgia Cancer Coalition Distinguished Cancer Scholar. He holds professional memberships with American Society of Clinical Oncology, American Association for Cancer Research, and International Association of Lung Cancer Study. Dr. Ramalingam plays an active role in the ECOG-ACRIN Cancer Research Group as the Chair of the Thoracic Malignancies Committee and as the Deputy Chair of Therapeutics Programs. He serves on several international, national and institutional committees. He is a member of the Medical Oncology Board Exam Committee for American Board of Internal Medicine.